Emerging Technologies Live
photo by stevepb from pixabay



Senolytics are drugs that are being developed to treat age-related diseases by targeting and eliminating senescent cells. These cells are thought to contribute to the decline in function that occurs with age, and senolytics could potentially help to slow down or even reverse this process. There is still much research to be done in this area, but senolytics show promise as a potential treatment for age-related diseases.

Some of the emerging trends in Senolytics include the use of small molecule drugs and biologics to target senescent cells, the development of novel delivery methods to target senescent cells, and the use of senolytics in combination with other therapeutic modalities such as immunotherapy.

See live data on companies, R&D, markets, and news

In order to access the link, you need a Mergeflow account.

No Mergeflow account yet?

No credit card, no software to install. Trial ends automatically after 14 days.

Teams and individuals from across industries and tech sectors use Mergeflow

Curious to see how it works?

Watch our free video course:

Frequently asked questions about the trial

After you sign up, you’ll receive an email from us with an account activation link. Over the course of the trial, we’ll send you emails with tips and tricks. The trial ends automatically after 14 days. No further obligations on your part.

No. We do not ask for your credit card up front, so you will only be charged when you decide to buy a subscription.

No. Mergeflow is a SaaS software that runs in any modern web browser. And because it’s a subscription, you get constant product updates.

You can pay your Innovator or Analyst subscription via credit card (American Express, MasterCard, Visa) or SEPA Direct Debits. The larger team plans, API and enterprise solutions can be paid via invoicing and bank transfer.


Yes. We don’t serve ads, we never sell anything you give us, and we protect your privacy.